Sonnet BioTherapeutics Inc (SONN)

[mick]

$SONN A Versatile Discovery Platform
Sonnet BioTherapeutics is leveraging its proprietary platform to develop a pipeline of single- and bi-functional therapies capable of stimulating and/or blocking immune-modulating targets.

Sonnet Concept
Our technology leverages a scaffold based on our proprietary albumin binding single chain antibody fragment (scFv) for delivery of recombinant human-cytokines (rH-cytokines) and other validated targets.

Following administration, the albumin-binding fragment attaches to naturally occurring albumin in the bloodstream and accumulates in inflamed tissue, including tumors.

By attaching a cytokine molecule to our albumin-binding fragment, we enable the cytokine to persist in the bloodstream and accumulate in the tumor micro-environment, affording it a greater chance to generate an anti-cancer immune response.